Jump to navigation Jump to search
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
Oral, Intravenous, Rectal
ATC code
Legal status
Legal status
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass495.526 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Nicomorphine


Most recent articles on Nicomorphine

Most cited articles on Nicomorphine

Review articles on Nicomorphine

Articles on Nicomorphine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Nicomorphine

Images of Nicomorphine

Photos of Nicomorphine

Podcasts & MP3s on Nicomorphine

Videos on Nicomorphine

Evidence Based Medicine

Cochrane Collaboration on Nicomorphine

Bandolier on Nicomorphine

TRIP on Nicomorphine

Clinical Trials

Ongoing Trials on Nicomorphine at Clinical

Trial results on Nicomorphine

Clinical Trials on Nicomorphine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Nicomorphine

NICE Guidance on Nicomorphine


FDA on Nicomorphine

CDC on Nicomorphine


Books on Nicomorphine


Nicomorphine in the news

Be alerted to news on Nicomorphine

News trends on Nicomorphine


Blogs on Nicomorphine


Definitions of Nicomorphine

Patient Resources / Community

Patient resources on Nicomorphine

Discussion groups on Nicomorphine

Patient Handouts on Nicomorphine

Directions to Hospitals Treating Nicomorphine

Risk calculators and risk factors for Nicomorphine

Healthcare Provider Resources

Symptoms of Nicomorphine

Causes & Risk Factors for Nicomorphine

Diagnostic studies for Nicomorphine

Treatment of Nicomorphine

Continuing Medical Education (CME)

CME Programs on Nicomorphine


Nicomorphine en Espanol

Nicomorphine en Francais


Nicomorphine in the Marketplace

Patents on Nicomorphine

Experimental / Informatics

List of terms related to Nicomorphine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Nicomorphine (Vilan, Subellan, Gevilan, MorZet) is the 3,6-dinicotinate ester of morphine. It is a strong opioid agonist analgesic two to three times as potent as morphine with a side effect profile similar to that of dihydromorphine, morphine, and diamorphine. Nicomorphine was patented as Vilan by Lannacher Heilmittel Ges. m.b.H. of Austria in 1957 and was first synthesized in 1904 either there or at another firm in what was then Austria-Hungary. The hydrochloride salt is available as ampoules of 10 mg/ml solution for injection, 5 mg tablets, and 10 mg suppositories. It is possible that other manufacturers distribute 10 mg tablets and other concentrations of injectable nicomorphine in ampoules and multidose vials. It is used, particularly in the German-speaking countries and elsewhere in Central Europe and some other countries in Europe and the former USSR in particular, for post-operative, cancer, chronic non-malignant and other neuropathic pain. It is commonly used in patient-controlled analgesia (PCA) units. The usual starting dose is 5–10 mg given every 3–5 hours.

The 3,6-diesters of morphine are drugs with more rapid and complete central nervous system penetration due to increased lipid solubility and other structural considerations. The prototype for this subgroup of semi-synthetic opiates is heroin and the group also includes dipropanoylmorphine, diacetyldihydromorphine, disalicylmorphine and others. Whilst this produces an enhanced "bang" when the drug is administered intravenously, it cannot be distinguished from morphine via other routes, although the different side effect profile, including lower incidence of nausea, is very apparent.

Side effects

Nicomorphine's side effects are similar to those of other opioids and include itching, nausea and respiratory depression. It is considered by doctors to be one of the better analgesics for the comprehensive mitigation of suffering, as opposed to purely clouding the noxious pain stimulus, in the alleviation of chronic pain conditions.[1]


Nicomorphine is regulated in much the same fashion as morphine worldwide but is a Schedule I controlled substance in the United States and was never introduced there.

Nicomorphine may appear on rare occasions on the European black market and other channels for unsupervised opioid users. It can be produced as part of a mixture of salts and derivatives of morphine by end users by means of treating morphine with nicotinic anhydride or related chemicals in an analogue of the heroin homebake process.

CAS number of hydrochloride: 35055-78-8
Free base conversion ratios of salts:
Nicomorphine Hydrochloride: 0.93


  1. Vadon P, Rehak P. Comparison of the analgesic effect of nicomorphine in two different solutions (German). Wiener Medizinische Wochenschrift. 1979 Apr 30;129(8):217-20.